Tuesday, January 13, 2004 11:58:30 AM
DNAP would run an analysis on a set of samples, provided and sorted by the customer, and provide classifier markers from the data for about $100,000.00.
(I think CMIH was going to obtain samples from African-Americans and try to extract (cancer?) data.)
Given this service, and the proposed scenario of a drug company that has run into a compatability issue in the late stages of development, what would make more sense to the drug company?
Take the DNA samples from the test subjects and hire DNAP to run an analysis to determine the appropriate classifier markers, or sell the drug and the sample data to DNAP for a fraction of it's eventual value?
$100K would seem like a pittance in comparison to the millions required for multistage testing.
Did the CMIH deal provide any downstream income to DNAP or was it just limited to the up front fee?
I'm just trying to assess the likelihood that DNAP will have access to such drug targets.
regards,
frog
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM